Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
-
REGULATORY Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
-
REGULATORY Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
-
REGULATORY Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
-
BUSINESS Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
-
ACADEMIA Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
-
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
-
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
-
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
-
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
-
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review
March 18, 2020
-
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
-
ORGANIZATION Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
-
BUSINESS Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
-
COMMENTARY Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
-
BUSINESS Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
-
REGULATORY Japan Cabinet OKs Bill to Allow Govt to Declare Emergency over Coronavirus
March 11, 2020
-
BUSINESS Japan’s 2020 Price Revision Hits Major Drugs with Double-Digit Slashes: Top 5 Product Survey
March 10, 2020
-
BUSINESS Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll
March 9, 2020
-
BUSINESS Chugai, Teijin Suffer Hefty 9% Cuts in 2020 Drug Price Revision: Jiho Poll
March 6, 2020
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…